[{"id":"917c2805-5f04-496c-b017-e050f4e87dd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01768338","created_at":"2021-01-18T07:46:52.906Z","updated_at":"2025-02-25T15:40:34.527Z","phase":"Phase 1","brief_title":"Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma","source_id_and_acronym":"NCT01768338","lead_sponsor":"Michael John Robertson","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab) • iboctadekin (SB-485232)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 03/01/2016","primary_completion_date":" 03/01/2016","study_txt":" Completion: 08/03/2017","study_completion_date":" 08/03/2017","last_update_posted":"2023-02-10"},{"id":"5ba9b1be-cf4a-4b86-9279-5b70eda2c3e3","acronym":"","url":"https://clinicaltrials.gov/study/NCT00500058","created_at":"2021-01-18T01:47:34.825Z","updated_at":"2024-07-02T16:37:19.575Z","phase":"Phase 1","brief_title":"A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18","source_id_and_acronym":"NCT00500058","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD20 • CD8 • IFNG • IL2RA • PTPRC • CD69 • FASLG • IL7R • NCAM1 • CD14 • CSF2 • ITGAM • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • IFNG • IL2RA • PTPRC • CD69 • FASLG • IL7R • NCAM1 • CD14 • CSF2 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • iboctadekin (SB-485232)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 07/31/2007","start_date":" 07/31/2007","primary_txt":" Primary completion: 03/04/2010","primary_completion_date":" 03/04/2010","study_txt":" Completion: 03/04/2010","study_completion_date":" 03/04/2010","last_update_posted":"2017-07-26"}]